Symbol
| SMAD3
| contributors: mct/ - updated : 06-04-2018
|
HGNC name
| SMAD family member 3
|
HGNC id
| 6769
|
Other morbid association(s)
|
Type | Gene Modification | Chromosome rearrangement | Protein expression | Protein Function
|
---|
tumoral
|  
|  
|  
|  
|
in acute T-cell lymphoblastic leukemia and in gastric carcinoma in the early stage | constitutional
|  
|  
| --low
|  
|
accelerates not only cutaneous wound healing and keratinocyte proliferation but also colonic epithelial cell proliferation | constitutional
|  
|  
| --over
|  
|
upregulation of ZFYVE9 and SMAD3 in cortex neurons might be involved in the development of intractable temporal lobe epilepsy | |
Susceptibility
|
to osteoarthritis |
Variant & Polymorphism
|
| |
Candidate gene
Marker
Therapy target
|
System | Type | Disorder | Pubmed |
diabete | | | |
inhibition of SMAD3 function has therapeutic potential for diabetic renal disease |
| | | |
| Smad3 -/- mice showed an increased number of proliferating epithelial cells with activation of the Wnt/beta-catenin pathway in the colonic crypts | |
mice lacking Smad3 are protected against tubulointerstitial fibrosis following unilateral ureteral obstruction as evidenced by blocking of EMT and abrogation of monocyte influx and collagen accumulation |